Fundraising Overview - The company raised a total of RMB 455.5322 million through its initial public offering, with a net amount of RMB 390.9331 million after deducting various issuance costs [1][2] - The funds were raised by issuing 20.200986 million shares at a price of RMB 22.55 per share [1] Fund Utilization and Balance - As of December 31, 2022, the company had a remaining balance of RMB 336.43 million in its fundraising account, with RMB 4.70846 million used for projects and RMB 1.69811 million for issuance costs [2] - By December 31, 2023, the remaining balance was RMB 236.3034 million, with RMB 9.35421 million utilized for projects [2] - As of December 31, 2024, the remaining balance was RMB 137.4138 million, with RMB 8.77753 million used for projects [2] - As of June 30, 2025, the remaining balance was RMB 114.5452 million, with RMB 2.37295 million utilized for projects [2] Fund Management - The company has established a fundraising management system to ensure the effective use of funds and protect investor rights [3] - Funds are stored in designated bank accounts, and a tripartite supervision agreement has been signed with the underwriter and banks [3] Project Completion and Remaining Payments - Several projects funded by the raised capital, including the R&D center and marketing network construction, have been completed, with remaining payments totaling RMB 30.1286 million [2][3] - The company has used part of the raised funds to replace self-raised funds for issuance costs, amounting to RMB 4.6433 million [6][11] Idle Fund Management - The company has approved the use of idle funds for cash management, with a limit of RMB 100 million [5][6] - As of June 30, 2025, RMB 42 million of idle funds were allocated for cash management [12]
西点药业: 2025年半年度募集资金存放与使用情况的专项报告